CANADIAN CANCER TRIALS GROUP – GI DISEASE SITE COMMITTEE

COLON
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO
DATE SATURDAY, APRIL 30th, 2016
TIME: 07:45 – 09:15
CHAIRS: DR. DEREK JONKER & DR. SHARLENE GILL

07:45 WELCOME AND INTRODUCTION
DR. D. JONKER / DR. S. GILL

07:50 UPDATES FROM FINAL ANALYSES

CO.23: A PHASE III RANDOMIZED STUDY OF BBI608 AND BEST SUPPORTIVE CARE VERSUS PLACEBO AND BEST SUPPORTIVE CARE IN PATIENTS WITH PRETREATED ADVANCED COLORECTAL CARCINOMA
DR. D. JONKER

ACTIVE/RECENTLY CLOSED TRIALS FOR UPDATE

08:00 IND 214: A PHASE I/II TRIAL OF MG1MA3 WITH AND WITHOUT ADVAC/MA3 IN PATIENTS WITH ADVANCED/METASTATIC COLORECTAL OR NON SMALL CELL LUNG CANCER
DR. D. JONKER

08:05 CO.21 (CHALLENGE): A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH EARLY STAGE COLON CANCER: A RANDOMIZED CONTROLLED TRIAL (CHALLENGE)
DR. K. COURNEYA & DR. C. BOOTH

APPROVED TRIALS IN DEVELOPMENT

08:10 CO.25 (FOCUS 4): MOLECULARLY STRATIFIED RCT PROGRAMME FOR SELECTION OF THERAPY IN METASTATIC CRC POST INDUCTION 1ST LINE TREATMENT
DR. R. GOODWIN

08:25 CO.26: A PHASE II/III TRIAL OF DURVALUMAB AND TREMELIMUMAB AND BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED COLORECTAL ADENOCARCINOMA REFRACTORY TO STANDARD THERAPIES
DR. E. CHEN

08:40 CO.27 (IROCAS): - AN ADJUVANT TRIAL OF MFOLFIRINOX VS MFOLFOX6 IN HIGH-RISK STAGE III COLON CANCER
DR. S. GILL
CANADIAN CANCER TRIALS GROUP – GI DISEASE SITE COMMITTEE

COLON
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO
DATE SATURDAY, APRIL 30th, 2016
TIME: 07:45 – 09:15
CHAIRS: DR. DEREK JONKER & DR. SHARLENE GILL

NEW CONCEPTS IN DEVELOPMENT

08:55 DREAM: ADJUVANT AZACITIDINE VERSUS OBSERVATION AFTER PERIOPERATIVE CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER: AN OPEN, MULTICENTRE, RANDOMIZED PHASE II TRIAL

DR. B. CHAN

INTERGROUP TASK FORCE UPDATE

09:05 ADJUVANT: RANDOMIZED PHASE III STUDY OF MFOLFOX6 WITH OR WITHOUT ATEZOLIZUMAB IN THE ADJUVANT TREATMENT OF PATIENTS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) RESECTED STAGE 3 COLON CANCER

DR. D. JONKER / DR. S. GILL

09:15 CLOSING REMARKS